Introduction {#Sec1}
============

Medication management in care homes is suboptimal \[[@CR1]\]. Despite various policy recommendations \[[@CR2]--[@CR7]\], the majority of care home residents continue to receive inappropriate medication, and a significant number of administration errors occur \[[@CR8]\]. Many residents are on multiple medications, and there is overuse of psychotropic medicines, as well as more general concern such as lack of biochemical monitoring of high-risk drugs including methotrexate, azathioprine, amiodarone, warfarin etc. and lack of regular medication review \[[@CR9]\]. Further, there is often poor communication between general practitioner (GPs), care home staff, community pharmacists, residents and their relatives, and a need for training of care home staff, many of whom may not have a theoretical understanding of the requirements for supply, storage, recording and administration of medicines. High staff turnover and the frailty of the resident population are further factors. It has been suggested that errors would be reduced if a single person took on overall responsibility for the medicines management in care homes. Our team proposed this should be a pharmacist independent prescriber (PIP) linked to the care home, and are undertaking a programme of work which has identified logistical and professional barriers to a PIP care home service, and devised solutions to address them \[[@CR10]\], devised a training programme for the PIPs to ensure they have the requisite competencies to deliver the service, and identified provisional measures of outcome \[[@CR11]\] in preparation for a definitive cluster randomised controlled trial (RCT) to compare the outcomes from the PIP service with usual care. A mixed-methods non-randomised feasibility study \[[@CR12]\] confirmed the acceptability and feasibility of the processes for participant identification, recruitment and informed consent. The PIP service was found to be acceptable to all stakeholders and benefits were reported by GPs and care home staff. Appropriate outcome measures and tools were confirmed and minor refinements were made to the service specification and RCT protocol. The definitive cluster RCT is ongoing and will complete in May 2020. An internal pilot within the definitive trial has confirmed: (i) the feasibility of recruiting and randomising sufficient GP practices, PIPs, care homes and residents; (ii) the availability of data for primary outcome at 3 months; (iii) confirmation that there are no intervention-related safety concerns and (iv) researcher blinding and unblinding \[[@CR12]\].

The definitive RCT was approved by ethics committees in England and Scotland, and registered with the ISRCTN registry (registration number ISRCTN 17847169). A protocol paper (protocol version 5 1.7.18) for the main trial, following SPIRIT guidance, has been submitted to BMC *Trials* \[[@CR13]\]. This current article describes the protocol for the Process Evaluation Protocol that accompanies the definitive RCT; it follows the 2014 guidance on process evaluations \[[@CR14], [@CR15]\] and details are in Process Evaluation Protocol version 4 11.12.18 available from the authors on request.

Causal assumptions {#Sec2}
==================

The definitive RCT is evaluating the efficacy and efficiency of implementing and delivering a PIP service and comparing outcomes for care home residents who receive the PIP service with outcomes for residents who continue to receive usual care \[[@CR13]\]. In total 44 GP/PIP/care home groups (subsequently referred to as triads) and 880 patients will be included in four geographical areas of East Anglia, Leeds, North East Scotland and Northern Ireland. As noted above, the problem is that medicines management in care homes is suboptimal and complex, because the frailty and comorbidities of residents means many are on multiple medications. A logic model was developed (Additional file [1](#MOESM1){ref-type="media"}: Appendix 1) to demonstrate how the proposed PIP service could address the various issues. The PIP intervention is described below.

The intervention {#Sec3}
----------------

At intervention care home(s), PIPs working in collaboration with the relevant GP(s), will assume responsibility for the medicines management of a mean of 20 care home residents living in one or more care homes associated with the GP practice. To ensure competency in professional role and study procedures, the recruited PIPs are qualified independent prescribers, and have attended a 2-day face-to-face training programme, which included an overview of the trial design, project delivery, and preparation for the role; the service specification and completion of the Pharmaceutical Care Plans (PCPs). This was followed by time to develop relationships with medical practices (for those unfamiliar with the practice), care homes and community pharmacists, including performing medication reviews with GPs and observing medication administration by care staff, before final sign-off by clinically qualified professionals independent of the research team.

A service specification for the PIPs has been developed iteratively in the earlier stages of the project, and is attached (Additional file [1](#MOESM1){ref-type="media"}: Appendix 2). In summary, it includes: reviewing a participating resident's medication and developing and implementing a PCPassuming prescribing responsibilitiessupporting systematic ordering, prescribing and administration processes within each care home, GP practice and supplying pharmacy where neededproviding training to staff in care home and GP practicecommunicating with GP practice, care home, supplying community pharmacy and study team

The control arm {#Sec4}
---------------

At each control care home, medicine management is according to usual practice, in which the GP(s) has responsibility for the medicines management of care home residents living in one or more care homes associated with the GP practice. Pharmacy provision is also according to usual practice in that area.

The CHIPPS RCT process evaluation {#Sec5}
---------------------------------

The aims of the process evaluation, described in this article are informed by the logic model and the stages of the Medical Research Council (MRC) process evaluation framework \[[@CR14], [@CR15]\]. These are listed below. To describe the intervention as delivered in terms of quality, quantity, adaptations and variations across triads and time (Table [1](#Tab1){ref-type="table"}).To explore the effects of individual intervention components on the primary outcomes (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).To investigate the mechanisms of impact (Table [2](#Tab2){ref-type="table"}).To describe the perceived effectiveness of relevant intervention components (including PIP training and care home staff training) from participant (GP, care home, PIP and resident/relative) perspectives (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).To describe the characteristics of GP, care home, PIP and resident participants to assess reach (Table [4](#Tab4){ref-type="table"}).To estimate the extent to which intervention delivery is normalised among the intervention healthcare professionals and related practice staff (Table [4](#Tab4){ref-type="table"}).If the service is found to be effective and efficient, to inform subsequent implementation.Table 1Implementation tasks and data collected as part of process evaluationTaskAim (what is being assessed)Data collectedData sourceProvide training for PIPsEffectiveness of trainingPIP views on trainingPost- training feedback forms (at end of 2-day training session)PIP interviewPIP questionnaireCompetencyCompetency assessments (feedback from independent assessors)Appropriateness of PCPs (20% sample; Additional file [1](#MOESM1){ref-type="media"}: Appendices 3,4)Views of stakeholders (interviews)PIP delivery of the interventionFidelity to interventionServices provided and frequency with which providedPIP activity logsNumber of pharmaceutical care plansPIP questionnaireQuality of medication reviewReview of 20% of pharmaceutical care plans*PCP* Pharmaceutical Care Plan; *PIP* pharmacist independent prescriberTable 2Mechanism of impact and data collected as part of process evaluationImpactMechanism of impactData collectedData sourceMedication changes identifiedPIP medication reviewRecommendations for change and rationalePharmaceutical care plansPIP interviewPIP questionnaireMedication changes madePIP prescribingTotal no. medications per patient at baseline and 6 monthsPharmaceutical care plansGP recordsNo. medications stopped per patient at 6 monthsPharmaceutical care plansGP recordsNo. medications started per patient at 6 monthsPharmaceutical care plansGP recordsNo. medications amended, e.g. dose change, formulation changePharmaceutical care plansGP recordsNo. antipsychotics/psychotropics prescribed at baseline and 6 monthsPharmaceutical care plansGP recordsCategorised description of drugs changed, stopped, startedResident medical recordsBiochemical monitoringPIP medication reviewRecommendations made for biochemical monitoringPharmaceutical care plansMedication errorsPIP medication reviewNumber of prescribing, dispensing and administration errorsPharmaceutical care plansGP recordsNon-patient-facing activities improved, e.g. medication storage advicePIP support for care homeServices provided and frequencyPIP activity logViews on usefulness of servicesCare home staff interviewsPIP interviewPIP questionnaireBetter/tailored training for staffPIP training for care home staffTraining provided and frequencyPIP activity logViews on usefulness of trainingCare home staff interviewsPIP interviewPIP questionnaireQuality of communication between care home, GP and community pharmacy improvedPIP input into improved communicationViews of care home staffCare home staff interviewsViews of GPsGP interviewViews of PIPsPIP interviewPIP questionnaire*GP* general practitioner; *PIP* pharmacist independent prescriberTable 3Outcomes and data collected as part of process evaluationAimOutcomeData collectedData sourceTo improve quality of care for those over 65 years old resident in care homesFallsFall rate per person at 3 monthsCare home falls recordFall rate per person at 6 monthsCare home falls recordQuality of lifeSelf-reported quality of lifeFace-to-face self-reported EQ-5D-5 L (only applicable for participants with capacity) at baseline, 3 months and 6 monthsCarer-assessed quality of lifeProxy EQ-5D-5 L (quality of life) at baseline, 3 months and 6 monthsPhysical functioningCarer-assessed physical functioningProxy Barthel Index (physical functioning) at baseline and 6 monthsHealth service utilisation and associated costsCosts of care (medication, healthcare team contacts, monitoring and tests)GP records at baseline and 6 monthsDBICalculate DBI based on medicationsGP records at baseline and 6 monthsTo assess intervention safetyMortalityInformation on numbers dying and time to death.Monthly call to care homesHospitalisations(Note: not always a negative marker of safety)Information on numbers hospitalisedMonthly call to care homesGlobal view^a^Perceptions of GPsGP interviewPerceptions of care home staffCare home staff interviewsPerception of residents/consultee/WPOAResident/consultee/WPOA interviewsPerceptions of PIPsPIP interviewAdverse events^a^New drug related symptomsStakeholder feedback using standard templateSerious adverse events^a^See hospitalisations/deathsMonthly call to care homesSudden unexpected serious adverse events^a^See hospitalisations/deathsFeedback from GPs/independent medical assessor on causal link with PIP intervention*DBI* Drug Burden Index; *EQ-5D-5 L* EuroQoL five-dimension, five-level questionnaire; *GP* general practitioner; *PIP* pharmacist independent prescriber; *WPOA* Welfare Power of Attorney^a^ Other than those noted, these are also primary and secondary outcomes for main trial and will be compared across groupsTable 4Contextual factors collected as part of process evaluationContextual factorData collectedData sourceBarriers to delivering the interventionFeedback from stakeholdersCare home staff interviewGP interviewPIP interviewNoMAD \[[@CR16]\] survey to GPs/PIPs and care home staffOther anecdotal feedbackFacilitators to delivering the interventionFeedback from stakeholdersCare home staff interviewsGP interviewPIP interviewNoMAD \[[@CR16]\] survey to GPs/PIPs and care home staffOther anecdotal feedbackSite and participant factorsInter PIP variationCompetencyVariation in outcomesReview of PCPs for both safety and missed opportunityGP interviewCare home interviewsEmployment statusBaseline PIP questionnaireQualificationsBaseline PIP questionnaireInter-site variationCare home factorsBaseline care home surveyResident factorsBaseline resident dataInter-location variationViews of researchersMeeting minutesNormalisation of intervention into routine practiceActions taken by participants to ensure the intervention worksCoherence(Making sense of the service)NoMAD survey \[[@CR16]\] to PIPs, care home staff, GPsGP interviewCare home staff interviewsPIP interviewCognitive participation(Engaging with the service)NoMAD \[[@CR16]\] survey to PIP, care home staff, GPsInterviews (GP and care home staff)PIP interviewCollective action(delivering the service/responding to the service)NoMAD \[[@CR16]\] survey to PIP, care home staff, GPsGP interviewCare home staff interviewsPIP interviewReflexive monitoring(appraising and reviewing the service)NoMAD \[[@CR16]\] survey to PIP, care home staff, GPsGP interviewCare home staff interviewsPIP interview*GP* general practitioner; *PIP* pharmacist independent prescriber

Methods {#Sec6}
=======

Design {#Sec7}
------

In line with the MRC guidance on process evaluation \[[@CR14], [@CR15]\] this mixed-methods process evaluation using qualitative and quantitative approaches will collect data on implementation of the intervention, mechanisms of impact, outcomes and contextual factors. The tasks, aims, data and data source for each of these are summarised in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}. All data is collected, from intervention arm participants only, after the 6-month study period is completed for an individual participant.

Implementation {#Sec8}
--------------

Data will be collected on the effectiveness of the training, and the services delivered by the PIPs (see Table [1](#Tab1){ref-type="table"} below) to provide an understanding of whether the PIPS were adequately prepared for the role and the fidelity with which it was delivered.

Mechanism of impact {#Sec9}
-------------------

Data will be collected to confirm the mechanism of impact of the intervention in achieving the desired aim of improved patient quality of care (Table [2](#Tab2){ref-type="table"}). This section draws particularly on the logic model and hypotheses for addressing the highlighted issues. Data will only be collected from the intervention group to see if any observed differences in outcomes between the groups can be explained by different components of the PIP service. None of these happen in the control (usual care) group.

Outcomes {#Sec10}
--------

The outcomes that are collected and which will be used in the process evaluation are described in Table [3](#Tab3){ref-type="table"}. The selected outcomes are those where there is a clear link to the intervention proposed and where they inform the process.

Contextual factors {#Sec11}
------------------

Any contextual factors identified which might have affected the delivery and impact of the intervention are described in Table [4](#Tab4){ref-type="table"}. This information may include factors related to individual personnel and organisations as well as macro-level issues such as Care Quality Commission requirements or head office requirements.

Data collection methods {#Sec12}
-----------------------

The following text refers to the data sources identified in Tables [1](#Tab1){ref-type="table"}--[4](#Tab4){ref-type="table"} .

Quantitative {#Sec13}
------------

Data sources related to training and pharmacist competency *Training feedback*: At each PIP training event, PIPs are asked to complete a feedback form at the end of the 2-day face-to-face session*Pre-intervention competency*: Following the training, PIPs submit their competency framework to one of the study competency assessors who discuss these with the PIP and signs them off as 'fit to practise' as a CHIPPS PIP, prescribes further training or that they are not competent to deliver the study*Review of PCPs*: Following an agreed process (Additional file [1](#MOESM1){ref-type="media"}: Appendices 3 and 4) a random 20% of PCPs are reviewed for appropriateness by study team members who are specialists in care of the elderly. Whilst this process is primarily about safety, the assessment templates also capture data on missed opportunities.

Data sources related to activity *PIP activity log:* Intervention PIPs are asked to keep an activity log of their daily activity detailing the time spent on tasks as listed in the service specification (Additional file [1](#MOESM1){ref-type="media"}: Appendix 2)*PIP survey*: Following each phase, intervention PIPs will be asked to complete a short questionnaire asking about their experiences and the extent to which they delivered aspects of the intervention focusing especially on non-medication review aspects of the service specification (the NoMAD survey \[[@CR16]\]).

Data sources related to prescribing

Most of the prescribing-associated data is collected as part of the main trial processes to assess effectiveness and efficiency of the intervention (GP records, healthcare utilisation, falls records, hospitalisations and deaths) and processes are detailed in the main trial protocol (version 5 1.7.18). The following lists additional data collected as part of the process evaluation *Adverse events*: Adverse events which are not deemed serious are reported using a standard template emailed to the Clinical Trials Unit. All study participants with a professional role (PIP GP, GP staff and care home staff) are made aware of this template and are asked to use this facility if they suspect any adverse event, whether or not there is a perceived causal relationship with the intervention*PCPs*: these are completed by the PIP as a clinical record of their actions including the rationale for these. Data extraction from these will inform the details of medication changes that underpin the global measures such as total number of medicines, British National Formulary categories most involved in changes, and overall Drug Burden Index (DBI). They will also include information on homely remedies and medications available from pharmacies (P medicines) and other retail outlets (general sale list medicines) which could result in therapeutic duplication

Data sources related to variability

Variability may be due to inherent non-modifiable differences across participating organisations, sites and individuals, or to the way the CHIPPS service has been delivered or normalised. The former will be explored using subgroup analyses and the latter by general estimating equations (GEEs) and applying normalisation process theory (NPT) via a NoMAD \[[@CR16]\] survey to all participating GPs, PIPS and care home staff at the end of each phase. These are described below. *Subgroup analyses:* The following subgroup analyses will be conducted. i.Comparison of intervention effect by care home types, i.e. nursing versus residential.ii.Comparison of intervention effect by the employment status of the PIPs, i.e. those PIPs who were previously employed, and therefore had an established working relationship, with the study GP practice, and those who were not).For both of the above an interaction term (between treatment and subgrouping factor) will be added to the primary model and formally tested for a non-zero value.*GEEs:* Any effect of the PIP intervention is likely to be mediated through a decrease in the DBI. This will be tested using a GEE, adjusting for group membership (this is in order to remove any effect of the PIP intervention on falls mediated via a different causal route).*NoMAD survey* \[[@CR16]\]: The NoMAD survey is an implementation measure based on the Normalisation Process Theory (NPT) \[[@CR17], [@CR18]\]. The survey form includes preliminary demography and general questions about experiences and satisfaction followed by four sections each relating to one of the NPT domains of coherence, cognitive participation, collective action and reflexive monitoring.

Qualitative {#Sec14}
-----------

Feedback from all stakeholders on their experiences and views of the intervention is a core part of this process evaluation. This will help contextualise the intervention and increase understanding of the process of implementation and any variation between sites and stakeholders.

### Interviews {#Sec15}

At the end of each phase of the intervention a purposive sample of up to three of each of GPs, care home managers, staff, residents and relatives (if available) in each of the four geographical areas will be invited to take part in a semi-structured interview. Sampling will be based on a maximum variation sample to reflect differences in site and PIP characteristics, e.g. PIP employment status, previous PIP experience, demographic profile of care home residents, rural or urban location. All PIPS will be invited to take part in an interview.

Interviews will be guided by a topic guide (Additional file [1](#MOESM1){ref-type="media"}: Appendix 5), developed from the qualitative outputs from the earlier non-randomised feasibility study \[[@CR12]\]. Topics will include participants' views of the PIP service implementation and delivery, communication between staff, perceived effectiveness of the intervention and the identification of any unintentional consequences. All aspects of the service will be probed and there will be specific probes for unforeseen effects to understand whether anything else about the service impacted positively or negatively on patient care or cost-effectiveness. In addition to the above topics, the PIP interview will explore their perception of the training programme and its utility.

### Conduct and analysis {#Sec16}

All participants invited to interview will be given an information sheet and consent form prior to participation. Ideally, interviews will be held face to face at a location of the interviewee's choice, but virtual modes will be considered for logistical reasons. All proceedings will be audio recorded and transcribed verbatim. Thematic analysis will draw on the NPT framework, but an inductive approach will enable recognition of unexpected emergent themes. Data will be managed in NVIVO.

### Documentary evidence {#Sec17}

Minutes of meetings will provide researcher-reported information on barriers, facilitators and other confounding factors that may have affected delivery of the trial, e.g. (recruitment challenges, reach).

Data integration/synthesis {#Sec18}
--------------------------

Once all process and main trial outcomes are reported, all the data sets (qualitative and quantitative) will be integrated \[[@CR19]\] using a triangulation approach to consider agreement, partial agreement, silence and dissonance across the findings. This will identify relevant actions, and clarify and relate causal pathways to experiences, providing an enriched means to explain unexpected outcomes, and identify optimal intervention contexts. Should the main RCT findings suggest the CHIPPS service is effective and efficient, the process evaluation will inform recommendations for implementation into routine services. The process evaluation will also be interrogated to understand reasons why the intervention has not been successful, including variable success rates in different sites.

Discussion {#Sec19}
==========

This detailed mixed-method process evaluation will provide an in-depth understanding of the interactions, barriers and facilitators which underpin the main study quantitative findings. For example, it will provide evidence of the effectiveness of the training in preparing the PIPs to deliver their role, show to what extent the mechanism of impact -- improved medication management -- has been implemented and the barriers and facilitators that have been encountered. Learning from these will enable decisions to be made about future roll-out of the PIP service. Further, if the main trial does not demonstrate that there has been an improvement in patient outcomes, it will allow an informed judgement to be made as to whether the service is wrong in principle or whether its implementation has been suboptimal. Our findings will be especially pertinent and timely as PIPs are already being introduced into care homes for roles such as we are evaluating. The systematic and comprehensive approach that is being adopted is in line with the MRC guidance on process evaluations \[[@CR14], [@CR15]\]. It will ensure data is captured on all aspects of the study, and allow an understanding of the implementation of the service, confirm its mechanism of impact, explore secondary, possibly explanatory, outcomes and any contextual factors. In summary, with so many interrelated factors involved it is important that a process evaluation is undertaken to enable identifyimg which elements of the service were deemed to be effective and explain any differences seen whilst also identifying adaptions, enablers and barriers.

Trial status {#Sec20}
------------

Resident recruitment for the RCT began in February 2018 and will continue until October 2019. Recruitment for the process evaluation started spring 2019 and will continue until June 2020.

Supplementary information
=========================

 {#Sec21}
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Dissemination policy {#FPar1}
====================

Trial results will be communicated to participants, other healthcare professionals, the public, and other relevant groups via local dissemination events, briefing papers, publications in academic and professional journals, conference presentations and other invited speaker events. These results will include the relevant findings from the process evaluation. The PPI representatives will be especially involved in advising on dissemination to the residents, relatives and care home stakeholders, and the wider public. The main trial results will be reported on the study website (<https://www.uea.ac.uk/chipps>) and via social media, e.g. the study Twitter account (\@CHIPPS_Study), but these may not include all the process evaluation unless directly relevant.
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